爱斯坦-巴尔病毒编码的潜膜蛋白2A通过在扩散型大B细胞淋巴瘤中对SYK/核因子-κB信号进行升级来促进免疫逃生
Xiang-Nan Jiang1, Dong Sheng1, Wan-Hui Yan1
1Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
埃普斯坦-巴尔病毒 (EBV) 编码的潜膜蛋白2A (LMP2A) 通过激活SYK/NF-κB信号,促进EBV阳性扩散型大B细胞淋巴瘤 (DLBCL) 的免疫逃逸,从而导致PD-L1表达的增加,并促进免疫逃逸.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
背景情况:
- 艾普斯坦-巴尔病毒 (EBV) 阳性扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有治疗结果差的侵袭性恶性瘤.
- 由EBV对PD-1/PD-L1通路的调节驱动的免疫逃生,有助于治疗耐药性.
研究的目的:
- 研究EBV编码的潜膜蛋白2A (LMP2A) 在EBV+DLBCL的免疫逃避机制中的作用.
- 探索LMP2A表达,信号通路 (SYK/NF-κB) 和DLBCL中的PD-L1表达之间的关系.
主要方法:
- 免疫组织化学被用来评估PD-L1,p65/NF-κB,pSYK和p-p65表达在EBV+DLBCL病例和没有LMP2A的EBV+DLBCL病例中.
- 免疫光测定评估了瘤透的CD4+和CD8+T细胞水平.
- 使用OCI-LY8细胞的体外实验检查了LMP2A,SYK和NF-κB信号对PD-L1表达的影响.
主要成果:
- 与LMP2A阳性的DLBCL病例相比,LMP2A阳性的DLBCL病例显示出增加的生物攻击性,较高的psyk,p-p65和PD-L1水平,以及较高的CD4+/CD8+比率.
- 在DLBCL细胞中的LMP2A转染上调 pSYK,p65,p-p65和PD-L1.
- 在LMP2A转移的DLBCL细胞中抑制p65或PSYK抑制PD-L1表达的淘汰.
结论:
- LMP2A可能模仿B细胞受体,激活SYK/NF-κB信号通路.
- 这种激活会影响瘤细胞和瘤免疫微环境上的PD-L1水平,促进EBV+ DLBCL的免疫逃避.
- 研究结果表明,对调节EBV+DLBCL治疗的潜在治疗策略.
更多相关视频
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
相关概念视频
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
The JAK-STAT Signaling Pathway
